Munich, Bayern 80539
Max Planck Institute for Innovation and Competition
Artificial intelligence, Machine learning, Intellectual property law, Technology, Digital economy
data-driven economy, data ownership, data base protection sui generis, access to data, access regulation, big data, protection of algorithms, trade secrets protection
artificial intelligence; AI-driven innovation; AI-generated output; copyright; database protection, human-computer interaction; innovation policy; intellectual property law; patents; trade secrets
access to medicines; COVID-19; compulsory licensing; know-how; innovation incentives; patents; vaccines; waiver of IP; WTO
EU Data Act Proposal, IoT data, access and use right, data economy, data-driven innovation
artificial intelligence; AI-generated inventions; Australian Federal Court; DABUS; inventor; inventorship; patent law
intellectual property, patents, compulsory licensing, licence, government use, European Commission, EU, harmonisation, judicial cooperation, emergency, urgency, crisis, negotiation, TRIPS, Doha Declaration, WTO, waiver, COVID, public interest, health, nutrition, environment, competition law, failure
artificial intelligence; AI-generated inventions; disclosure; evolutionary algorithms; genetic programming; inventive step; inventor; machine learning; obviousness; patent law; patentability
European law, data-driven economy, smart products, data ownership, data producer’s right, access to data, data portability.
CRISPR/Cas technology, genome editing, patents, cumulative innovation, patent thicket, anticommons
COVID-19, IP waiver, TRIPS flexibilities, Ministerial decision, WTO
CRISPR; genome editing; intellectual property; patents; plant varieties
Patent, injunctive relief, injunction, proportionality, public interest, complex products, non-practicing entities, standard-essential patents, good faith, trade secrets, Düsseldorf proceedings, 'fishing expeditions'
Pharmaceutical FDI, regualtion, comparative policy and law analysis
· Patent, injunctive relief, injunction, proportionality, public interest, complex products, non-practicing entities, standard-essential patents, good faith, trade secrets, Düsseldorf proceedings, “fishing expeditions”
pharmaceutical innovation, clinical research, data protection, data disclosure, European Medicines Agency
Clinical trial data; pharmaceutical foreign direct investment; investor-state arbitration; intellectual property; investment law
pharmaceutical patents, pharmaceutical patent policy, comparative intellectual property law
data ownership; data-driven innovation; data-driven economy
Drug innovation, clinical trial data, access, confidentiality, 'research commons'
Clinical trial data, Access, The European Medicines Agency, Commercially confidential information
innovation incentives; drug regulation; drug exclusivities
All content on this site: Copyright © 2023 Elsevier Inc., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.
To learn more, visit
This page was processed by aws-apollo-l100 in 1.223 seconds